| Firm | Analyst |
|---|---|
| Banc of America Securities | William T. Ho |
| Barclays Capital | Jim Birchenough, M.D. |
| BMO Capital Markets | Jason Zhang, Ph.D. |
| Canaccord Adams | Adam Cutler |
| Cowen & Co. | Phil Nadeau, Ph.D. |
| CRT Capital Group | Leah A. Hartman |
| Fortis Bank | Patrick Moriarty, Ph.D. |
| JPMorgan | Cory Kasimov |
| Lazard Capital Markets | Matthew S. Osborne |
| Leerink Swann and Co. | Jonas V. Alšenas, D.V.M. |
| Merrill Lynch | Thomas McGahren, M.D., J.D. |
| Natixis Bleichroeder | Jon LeCroy, M.D. |
| Needham & Company | Mark Monane, M.D. |
| Oppenheimer & Co. | Bret Holley, Ph.D. |
| Piper Jaffray | Thomas Wei |
| Summer Street Research Partners | Carol Werther |
| The Robins Group | Ruthanne Williams Roussel |
| ThinkPanmure | Soham Pandya |
| UBS | Jeff Elliott, Ph.D. |
| Wachovia Capital Markets | Aaron S. Reames |
Arena Pharmaceuticals, Inc. is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Arena Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Arena Pharmaceuticals, Inc. or its management. Arena Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
(Note: This page was last updated on: September 17, 2008.)